Exploring the benefits of nanotechnology for cancer drugs in different stages of the drug development pipeline

The cost to research and develop each successful new drug is projected to be upwards of US$ 2.8billion (2). [...]approaches to optimize and accelerate this timeline, especially for products applicable to life-threatening diseases such as cancer, are essential. [...]it is estimated that only one drug...

Full description

Saved in:
Bibliographic Details
Published in:Nanomedicine (London, England) England), 2020-11, Vol.15 (26), p.2539-2542
Main Authors: Apolinário, Alexsandra Conceição, Hirata, Amanda Soares, Anjos Miguel, Rodrigo dos, Costa-Lotufo, Leticia Veras, Pessoa, Adalberto, La Clair, James J, Fenical, William, Lopes, Luciana Biagini
Format: Article
Language:English
Subjects:
Bioavailability
Breast cancer
Cancer therapies
Clinical trials
Drugs
E coli
Enzymes
fenretinide
L-asparaginase
Melanoma
Nanotechnology
Oral administration
Pharmaceutical industry
Pharmacokinetics
Product development
Proteins
R&D
Research & development
seriniquinone
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The cost to research and develop each successful new drug is projected to be upwards of US$ 2.8billion (2). [...]approaches to optimize and accelerate this timeline, especially for products applicable to life-threatening diseases such as cancer, are essential. [...]it is estimated that only one drug is approved from every 5000-10,000 compounds that enter the research and development pipeline (3). The molecule was initially aimed for dermatological use, but the structural modification did not translate into successful application. [...]this drug was transferred for studies at the National Cancer Institute (MD, USA). Forty years have passed since the first preclinical assay was conducted and no formulation is available for FEN application for cancer therapy or chemoprevention so far. [...]additional efforts to eliminate this gap are urgent.
ISSN:1743-5889
1748-6963
DOI:10.2217/nnm-2020-0290